Total Funding
21
44
Total FundingVenture - Series Unknown raised
Growth Score
-33 pts
Heat Score
-15 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
95486
RENOVION is a clinical stage pharmaceutical company that provides nebulized therapy.
- Daniel Copeland: Chief Executive OfficerPast Role: GlaxoSmithKline, Manager - Commercial Analytics
Carolyn Durham: Chief Scientific OfficerPast Role: Kenan-Flagler Business School, Researcher
About the Company
Renovion company is a pharmaceutical corporation with therapy for chronic inflammatory airway diseases. The company’s flagship pharmaceutical product, Arina-1, is still in the pre-clinical stages. Renovion was formed in 2013 to leverage a pharmaceutical discovery at the University of North Carolina-Chapel Hill that reduces infection and addresses
airway inflammation through the use of a novel therapy.
